博济医药 reported revenue of ¥0.45B for the period ended 2026-06-30, +25.6% year on year. Net income was ¥0.04B, a 8.3% net margin on a 25.8% gross margin. The largest revenue line is 临床研究服务 at 79% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.45B | +25.6% |
| Gross profit | ¥0.12B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.04B | +115.0% |
| Gross margin | 25.8% | Net margin 8.3% |
| Revenue Q/Q | +6.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 临床研究服务 | ¥0.36B | 79.3% |
| 临床前研究服务 | ¥0.06B | 12.4% |
| 其他咨询服务 | ¥0.02B | 5.0% |
| 其他(补充) | ¥0.01B | 2.3% |
| 自主研发及技术成果转化服务 | ¥0.00B | 1.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.34B | 74.2% |
| R&D | ¥0.02B | 5.2% |
| SG&A | ¥0.06B | 12.4% |
| Tax & other | ¥0.00B | 0.6% |
| Item | Amount |
|---|---|
| Total assets | ¥1.70B |
| Total liabilities | ¥0.58B |
| Shareholders' equity | ¥1.11B |
| Equity / assets | 65.7% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | 8% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
科隆股份 ・ 九强生物 ・ 凯发电气 ・ 道氏技术 ・ 正业科技 ・ 金盾股份 ・ 迦南科技 ・ 中光防雷 ・ 伊之密 ・ 苏试试验 ・ 南华仪器 ・ ST浩丰
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies